Friday, Jan. 22, 2016, 31 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.25 to $13,944,713.80.

Highlighted Stocks Traded by Insiders:

Synovus Financial (SNV) - FREE Research Report

Bentsen Tim E, who is Director at Synovus Financial, bought 2,700 shares at $28.09 on Jan. 22, 2016. Following this transaction, the Director owned 7,949 shares meaning that the stake was boosted by 51.44% with the 2,700-share transaction.

The shares most recently traded at $28.84, up $0.75, or 2.6% since the insider transaction. Historical insider transactions for Synovus Financial go as follows:

  • 4-Week # shares bought: 900
  • 4-Week # shares sold: 5,430
  • 12-Week # shares bought: 900
  • 12-Week # shares sold: 5,430
  • 24-Week # shares bought: 900
  • 24-Week # shares sold: 5,430

The average volume for Synovus Financial has been 1.1 million shares per day over the past 30 days. Synovus Financial has a market cap of $3.7 billion and is part of the financial sector and banking industry. Shares are down 9.85% year-to-date as of the close of trading on Friday.

Synovus Financial Corp. operates as the bank holding company for Synovus Bank that provides various financial products and services. It offers integrated financial services, including commercial and retail banking, financial management, insurance, and mortgage services. The stock currently has a dividend yield of 1.71%. The company has a P/E ratio of 17.3. Currently, there are 4 analysts who rate Synovus Financial a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNV - FREE

TheStreet Quant Ratings rates Synovus Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Synovus Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DexCom (DXCM) - FREE Research Report

Sayer Kevin R, who is President & CEO at DexCom, sold 7,000 shares at $75.00 on Jan. 22, 2016. Following this transaction, the President & CEO owned 336,402 shares meaning that the stake was reduced by 2.04% with the 7,000-share transaction.

The shares most recently traded at $73.67, down $1.33, or 1.81% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 3,560
  • 12-Week # shares sold: 36,465
  • 24-Week # shares sold: 144,350

The average volume for DexCom has been 724,800 shares per day over the past 30 days. DexCom has a market cap of $5.9 billion and is part of the health care sector and health services industry. Shares are down 9.62% year-to-date as of the close of trading on Friday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently, there are 13 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jones Lang LaSalle (JLL) - FREE Research Report

Penrose Sheila A, who is Director at Jones Lang LaSalle, sold 1,000 shares at $141.00 on Jan. 22, 2016. Following this transaction, the Director owned 49,727 shares meaning that the stake was reduced by 1.97% with the 1,000-share transaction.

The shares most recently traded at $138.39, down $2.61, or 1.89% since the insider transaction. Historical insider transactions for Jones Lang LaSalle go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 16,000
  • 24-Week # shares sold: 19,000

The average volume for Jones Lang LaSalle has been 304,900 shares per day over the past 30 days. Jones Lang LaSalle has a market cap of $6.2 billion and is part of the financial sector and real estate industry. Shares are down 12.08% year-to-date as of the close of trading on Friday.

Jones Lang LaSalle Incorporated, a financial and professional services company, provides commercial real estate and investment management services worldwide. The stock currently has a dividend yield of 0.42%. The company has a P/E ratio of 14.3. Currently, there are 3 analysts who rate Jones Lang LaSalle a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JLL - FREE

TheStreet Quant Ratings rates Jones Lang LaSalle as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Jones Lang LaSalle Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.